A Clinical Study to Map the HLA Genomic Region in the Greek Population

ConditionsHealthy Respiratory Disease Chronic Renal Failure Cardiovascular Diseases Metabolic Disease Psychiatric Disorder Neurologic Disorder Gastrointestinal Diseases Haematologic Disease Rheumatologic Disease

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorAthens LifeTech Park

About this trial

The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.

Eligibility criteria

Qualifiers

possess a Greek social security number and are visiting hospitals/clinics, and/or other private laboratory institutions (incl. clinics and health care groups) as part of standard clinical practice in Greece,

are willing and able to provide written informed consent to participate in the study according to the study protocol.

Disqualifiers

Subjects not able to provide written informed consent (e.g. ICU patients, mental illness patients, lack of legal capacity).

bone marrow transplant

stem cell transplant

blood transfusion less than two weeks prior to buccal swab sample collection

Trial design

Treatments tested in this trial

Not listed

Trial groups

12,000 Participants

are grouped into 1 trial group

Locations8

Select a site below to view it on the map.

Sponsors and collaborators

Athens LifeTech Park

Lead sponsor

Galatea.Bio

Collaborator

Source ClinicalTrials.gov